Other languages Senti Biosciences, Inc.

Equities

SNTI

US81726A1007

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-27 pm EDT			5-day change	1st Jan Change
0.3228 ^USD	-5.09%		-8.03%	-51.09%

May. 17	Senti Biosciences, Inc. Announces Executive Changes	CI
May. 09	Senti Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Senti Biosciences, Inc. Announces Executive Changes	May. 17
Senti Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09
Senti Biosciences, Inc. Announces Executive Changes	May. 02
Senti Biosciences, Inc. Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia	Apr. 30
Senti Biosciences, Inc. Announces Resignation of Deborah Knobelman as Treasurer and Head of Corporate Development, Effective May 3, 2024	Apr. 26
Senti Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 21
Senti Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 21
Spark Therapeutics, Inc. Announces Workforce Reduction	Jan. 05
Top Premarket Gainers	Dec. 22
Senti Biosciences, Inc. Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	Dec. 22
Senti Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 13
Senti Biosciences, Inc. Announces New Strategic Collaboration with Celest Therapeutics Co. Ltd	Nov. 06
Senti Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11
Senti Biosciences, Inc. Announces Resignation of Philip Lee as Chief Technology Officer	23-08-10
GeneFab, LLC acquired Rights, title and interest in certain of the assets from Senti Biosciences, Inc. for $37.8 million.	23-08-09
Senti Biosciences, Inc. Highlights Initial Gene Circuit Data from Collaborations At the American Society of Gene and Cell Therapy Annual Meeting	23-05-20
Senti Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09
Senti Biosciences, Inc. Highlights Preclinical Data from Multiple Gene Circuit Enabled Cell Therapy Programs At Annual American Association for Cancer Research Meeting	23-04-17
Senti Biosciences, Inc. Announces Strategic Plan to Focus Research and Development Efforts on Lead Oncology Candidate SENTI-202	23-03-22
Senti Biosciences, Inc. Auditor Raises 'Going Concern' Doubt	23-03-21

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Senti Biosciences, Inc.

Equities

SNTI

US81726A1007

Other languages

Filters